JNJ240726P138000
- 0.03
- 0.000.00%
Johnson & Johnson Newsroom
Alvotech Launches First Biosimilar of J&J's Stelara in Europe
Sector Update: Health Care Stocks Rise in Monday's Premarket Hours
Health care stocks were advancing premarket Monday with the Health Care Select Sector SPDR Fund (XLV) 0.3% higher and the iShares Biotechnology ETF (IBB) up 0.5% recently.IQVIA Holdings (IQV) was up
After Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug Candidate
Monday, Addex Therapeutics (NASDAQ:ADXN) announced its partner Janssen Pharmaceuticals, Inc, a unit of Johnson & Johnson (NYSE:JNJ), has discontinued the development of ADX71149 (JNJ-40411813) in epilepsy.
Johnson & Johnson Seeks FDA OK of Spravato as Monotherapy
Johnson & Johnson is seeking Food and Drug Administration expanded approval of its Spravato nasal spray as a lone therapy for adults with treatment-resistant depression.
Express News | Johnson & Johnson Submits Supplemental New Drug Application To FDA Seeking Approval Of SPRAVATO CIII Nasal Spray In Treatment-Resistant Depression
Express News | Johnson & Johnson Seeks U.S. FDA Approval of Spravato® (Esketamine) as the First and Only Monotherapy for Adults With Treatment-Resistant Depression
Guggenheim Adjusts Johnson & Johnson's Price Target to $156 From $160, Maintains Neutral Rating
Johnson & Johnson (JNJ) has an average rating of outperform and price targets ranging from $155 to $215, according to analysts polled by Capital IQ.Price: 154.67, Change: -0.02, Percent Change: -0.01
Express News | J&J : Guggenheim Cuts Target Price to $156 From $160
Buy Rating Affirmed for Johnson & Johnson on Strong Growth and Strategic Acquisitions
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on July 18.
Express News | Addex Therapeutics - Janssen Informed Co It Discontinued Development of Adx71149 (Jnj-40411813) in Epilepsy
Kamala Harris' Potential Impact on Health Care Stocks
With President Joe Biden earlier Sunday saying he will end his campaign for re-election and endorsing Vice President Kamala Harris, the focus now turns on her positions on issues.
Here Are Big Pharma's Leading Blockbuster Makers
Has Johnson & Johnson's (NYSE:JNJ) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Johnson & Johnson's (NYSE:JNJ) stock is up by a considerable 6.2% over the past month. Given that stock prices are usually aligned with a company's financial performance in the long-term, we
Possible Bearish Signals With Johnson & Johnson Insiders Disposing Stock
Express News | Goldman Sachs Maintains Neutral on Johnson & Johnson, Lowers Price Target to $155
A Quick Look at Today's Ratings for Johnson & Johnson(JNJ.US), With a Forecast Between $169 to $185
On Jul 19, major Wall Street analysts update their ratings for $Johnson & Johnson(JNJ.US)$, with price targets ranging from $169 to $185.Morgan Stanley analyst Terence Flynn maintains with a hold
HSBC Adjusts Price Target on Johnson & Johnson to $174 From $170, Maintains Buy Rating
Johnson & Johnson (JNJ) has an average outperform rating and a price target range of $155 to $215, according to analysts polled by Capital IQ.Price: 155.01, Change: -0.41, Percent Change: -0.27
Dividend Roundup: Goldman Sachs, Johnson & Johnson, Qualcomm, Caterpillar, and More
What Are the Most Profitable Stocks of All Time? The Answer Might Surprise You.
An academic with a large following on Wall Street recently published a paper showing the stocks that have seen the strongest returns over time
J&J Ends Work on Addex Epilepsy Drug Candidate ADX71149: Report